Program
Diphenhydramine
Also written as “Ibuprofen and Diphenhydramine Citrate”, “Diphenydramine” and “Diphenhydramine Hydrochloride Injection”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Nasal Obstruction · Multiple Sclerosis · Depressive Disorder, Major · Urticaria, led by 9 companies.
Drug pageDiphenhydramine: every studyMany companies study it; this page follows only the 13 they lead. All 67 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 40 open or running | phase 4since Mar 20, 2008 | Mar 20, 2008 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| Lumara Healthits history only | 10 open or running | phase 2since Dec 26, 2007 | Dec 26, 2007 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| Otsukaits history only | 10 open or running | phase 1since Nov 25, 2012 | Nov 25, 2012 | none ahead |
| Overseas Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
| Procter and Gambleits history only | 10 open or running | phase 4since Oct 14, 2015 | Oct 14, 2015 | none ahead |
| TerSera Therapeuticsits history only | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Reddy's Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2010First studies: 2 phase 1 studies in HealthyFirst studyNCT01053338, NCT01053208
TargetBeta
“Histamine H1 receptor antagonist; Histamine H1 receptor antagonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| fexofenadinerule | Sanofi | phase 4 | 38 |
| bilastinerule | faes-farma-s-a | phase 4 | 19 |
Studies
All 2 Dr. Reddy's Laboratories leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01053338Healthy · India | 1 | Completed | Apr 2008 | 40 |
| NCT01053208Healthy · India | 1 | Completed | Apr 2008 | 40 |
How it is read
Names in the registry
- “Diphenhydramine”, 2 entries
- “Ibuprofen and Diphenhydramine Citrate”, 2 entries
- “Diphenydramine”, 1 entry
- “Diphenhydramine Hydrochloride Injection”, 1 entry
- “Diphenhydramine 50 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 2 studies
- Nasal Obstruction, 2 studies
- Multiple Sclerosis, 1 study
- Depressive Disorder, Major, 1 study
- Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.